Robert Nelsen bought $10.0M of PRME
director, owner at Prime Medicine, Inc.. 3,030,300 shares at an average of $3.30, traded Aug 1, 2025, filed Aug 1, 2025.
Score components
- +15RoleDirector
- +25Trade size$10.0M at market
- +10Relative to holdingsHoldings up 95%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -19.8%, 3m +22.3%, 6m -5.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-25-013462, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 1, 2025 | POpen-market purchase Common Stockindirect: By ARCH Venture Fund XII, L.P. | +3,030,300 | $3.30 | $10.0M | 6,230,300 | Aug 1, 2025 |
Related signals
Other insiders at Prime Medicine, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | Prime Medicine, Inc. | Gv 2021 Gp, L.l.c. owner | $5.0M 1,500,000 shares | +85% | |
| 57Moderate | Prime Medicine, Inc. | ARCH Venture Partners X, LLC owner | $10.0M 3,030,300 shares | +95% | |
| 57Moderate | Prime Medicine, Inc. | ARCH Venture Partners XII, LLC owner | $10.0M 3,030,300 shares | +95% | |
| 0Weak | Prime Medicine, Inc. | David R. Liu owner | $53k 21,000 shares | +0% | |
| 0Weak | Prime Medicine, Inc. | David R. Liu owner | $45k 21,000 shares | +0% | |
| 0Weak | Prime Medicine, Inc. | David R. Liu owner | $31k 21,000 shares | +0% | |
| 0Weak | Prime Medicine, Inc. | David R. Liu owner | $34k 21,000 shares | +0% | |
| 38Weak | Prime Medicine, Inc. | Richard Brudnick Chief Business Officer | $24k 20,000 shares | - | |
| 48Moderate | Prime Medicine, Inc. | Ann L. Lee Chief Technical Officer | $113k 100,000 shares | - | |
| 59Moderate | Prime Medicine, Inc. | Allan Reine Chief Executive Officer | $147k 125,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.